2024 ASCO® Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
Playback speed
10 seconds
ASCO® 2024 Insights: "OBX-115, IL2-Sparing Engineered TIL Cell Therapy for Immune Checkpoint Inhibitor-Resistant Unresectable/Metastatic Melanoma"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Rodabe Amaria
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Rodabe Amaria
37 views
June 11, 2024
Comments 0
Login to view comments.
Click here to Login